Analysts expect STAAR Surgical to report Q3 2026 revenue of $78.73 million and EPS of $0.05, with the current $24.54 stock price trading at an 11% discount to the $27.67 average analyst target. The central narrative for this report is the company’s performance in China as it laps a particularly difficult year-over-year comparison involving a one-time $25.9 million order from 2025.
While total revenue is projected to decline roughly 17% due to this high baseline, investors are looking for continued underlying unit growth in the EVO ICL lens family and evidence of stabilizing margins. Recent positive signals include an upgrade to 'Buy' from Stifel in late September and the approval of a new $50 million share buyback program.